EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Five-year durability in cell and gene therapy: evidence review and implications for payer coverage

Elias C Pittos, Joe DePinto iD

Expert Review of Pharmacoeconomics & Outcomes Research · 14.09.2026 · 26 (8) · 1031-1050

DOI: 10.1080/14737167.2026.2723931 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, online erschienen am 06.09.2026. Verfasst von Elias C Pittos und 1 weiteren Autor:innen. Beteiligte Einrichtung: InspiroGeneTM by McKesson, Irving, TX, USA. Hauptthemen laut MEDLINE: Genetic Therapy, Cell- and Tissue-Based Therapy. Die Arbeit nennt 120 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: McKesson Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Cell and gene therapies (CGTs) offer the potential for durable clinical benefit following a single administration. Although early regulatory approvals were often based on limited follow-up, an increasing number of U.S. Food and Drug Administration (FDA)-approved CGTs now report extended durability data from clinical trials and real-world evidence (RWE) studies. AREAS COVERED: This report synthesizes publicly available long-term follow-up (LTFU) evidence for FDA-approved CGTs in the United States, with a focus on durability of clinical benefit and the implications for payer coverage and reimbursement. Long-term efficacy and safety data for marketed CGTs were identified through a review of peer-reviewed publications and publicly available conference abstracts and presentations. As of December 2025, 21 therapies (62%) report follow-up extending to 5 years or longer. The review examines the available durability evidence and explores its relevance to ongoing discussions around durability-related uncertainty and the role of LTFU and real-world evidence in assessing CGT outcomes. EXPERT OPINION: Growing LTFU evidence suggests that durable clinical benefit can be achieved across multiple CGT platforms and disease settings. While uncertainties remain, accumulating data may help reduce durability-related uncertainty and inform payer coverage, reimbursement, and value assessment discussions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic TherapyCell- and Tissue-Based TherapyHumansUnited StatesTime FactorsInsurance CoverageUnited States Food and Drug AdministrationInsurance, Health, Reimbursement

Stichwörter der Autor:innen

Adeno-associated viral (AAV) gene therapycell and gene therapy (CGT)chimeric antigen receptor (CAR) T-cell therapylentiviral vector (LVV) gene therapylong-term follow-up (LTFU)payer coveragereal-world evidence (RWE)therapeutic durability

Autor:innen und Institutionen

  • InspiroGeneTM by McKesson, Irving, TX, USA.

ORCID-Profile: Joe DePinto

Förderung

  • McKesson Corporation

Zitieren

APA

Pittos, E. C., & DePinto, J. (2026). Five-year durability in cell and gene therapy: evidence review and implications for payer coverage. Expert Review of Pharmacoeconomics & Outcomes Research, 26(8), 1031-1050. https://doi.org/10.1080/14737167.2026.2723931

Vancouver

Pittos EC, DePinto J. Five-year durability in cell and gene therapy: evidence review and implications for payer coverage. Expert Review of Pharmacoeconomics & Outcomes Research. 2026;26(8):1031-1050. doi:10.1080/14737167.2026.2723931

BibTeX
@article{Pittos2026,
  author = {Pittos, Elias C and DePinto, Joe},
  title = {Five-year durability in cell and gene therapy: evidence review and implications for payer coverage},
  journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
  year = {2026},
  volume = {26},
  number = {8},
  pages = {1031--1050},
  doi = {10.1080/14737167.2026.2723931}
}
Kostenlos starten →